000079548 001__ 79548
000079548 005__ 20221221141551.0
000079548 0247_ $$2doi$$a10.1016/j.atherosclerosis.2018.06.870
000079548 0248_ $$2sideral$$a107063
000079548 037__ $$aART-2018-107063
000079548 041__ $$aeng
000079548 100__ $$aMarco-Benedí, V.
000079548 245__ $$aDisappearance of recurrent pancreatitis after splenectomy in familial chylomicronemia syndrome
000079548 260__ $$c2018
000079548 5060_ $$aAccess copy available to the general public$$fUnrestricted
000079548 5203_ $$aBackground and aims: Recurrent pancreatitis is a severe complication of familial chylomicronemia syndrome (FCS) mainly secondary to lipoprotein lipase deficiency. The mechanism and interindividual variability of pancreatitis in FCS are not fully understood, but abnormalities in the drainage system of pancreatic veins could be involved.
Methods and results: Two cases of typical FCS are described with a past history of recurrent pancreatitis that dramatically improved after splenectomy performed in both cases for reasons non-related to FCS.
Conclusions: These are the first reports of the disappearance of pancreatitis after splenectomy in FCS and they should be considered of anecdotal nature at this time. The disappearance of pancreatitis following splenectomy could be in part due to subsequent improvements in pancreatic drainage. Extrahepatic portal hypertension induced by hypertriglyceridemic splenomegaly leading to pancreatic congestion could also be a contributing factor.
000079548 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII-ERDF/CIBERCV-CB16-11-00451$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/IIS16-0114$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PIE16-00022$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI15-01983
000079548 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000079548 590__ $$a4.255$$b2018
000079548 591__ $$aPERIPHERAL VASCULAR DISEASE$$b12 / 65 = 0.185$$c2018$$dQ1$$eT1
000079548 591__ $$aCARDIAC & CARDIOVASCULAR SYSTEMS$$b37 / 136 = 0.272$$c2018$$dQ2$$eT1
000079548 592__ $$a1.748$$b2018
000079548 593__ $$aCardiology and Cardiovascular Medicine$$c2018$$dQ1
000079548 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000079548 700__ $$0(orcid)0000-0002-9647-0108$$aLamiquiz-Moneo, I.
000079548 700__ $$aÁlvarez-Sala, L.A.
000079548 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, F.$$uUniversidad de Zaragoza
000079548 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000079548 773__ $$g275 (2018), 342-345$$pAtherosclerosis$$tAtherosclerosis$$x0021-9150
000079548 8564_ $$s680018$$uhttps://zaguan.unizar.es/record/79548/files/texto_completo.pdf$$yPostprint
000079548 8564_ $$s8029$$uhttps://zaguan.unizar.es/record/79548/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000079548 909CO $$ooai:zaguan.unizar.es:79548$$particulos$$pdriver
000079548 951__ $$a2022-12-21-14:00:57
000079548 980__ $$aARTICLE